

10

**Impact of Rapid On-Site Evaluation on Adequacy of Endoscopic Ultrasound–Guided Fine-Needle Aspiration for Solid Pancreatic Lesions: A Systematic Review and Meta-Analysis**

Anna Matynia, MD<sup>1</sup>, Robert Schmidt, MD, PhD, MBA<sup>1</sup>, Gonzalo Barraza, MD<sup>2</sup>, Lester Layfield, MD<sup>2</sup>, Douglas G. Adler, MD<sup>3</sup>

<sup>1</sup>Departments of Pathology and <sup>3</sup>Gastroenterology, University of Utah, Salt Lake City, Utah; <sup>2</sup>Department of Pathology, University of Missouri, Columbia, Missouri

Rapid on-site evaluation (ROSE) has the potential to improve adequacy rates for endoscopic ultrasound–guided fine-needle aspiration (EUS-FNA) of solid pancreatic lesions. Previous studies published on the impact of ROSE report variable results, and, to our knowledge, a systematic review has not been done on this subject. We performed a systematic review and meta-analysis of studies reporting the adequacy rates for EUS-FNA of solid pancreatic lesions. Studies were assessed by 2 independent reviewers. Random effects meta-analysis model was used to determine adequacy rate. Meta-regression was used to assess the impact of ROSE on adequacy. Heterogeneity was assessed using Higgins I-squared statistic. The initial search produced 3,672 studies, and we identified 73 studies that met our inclusion criteria. The average adequacy rate for all studies was 96.0% (95% confidence interval [CI], 95.3%-96.7%). There was significant heterogeneity across all studies (I-squared = 78.4;  $P = .000$ ). Subgroup analysis showed that ROSE was associated with only a 3% improvement in adequacy rates, compared with studies without ROSE ( $P = .044$ ). The adequacy rate for studies using ROSE was 96.6% (95% CI, 95.8%-97.5%) compared with 93.0% (95% CI, 90.7%-95.2%) for studies that did not use ROSE. On average, adequacy rates are high, but there is considerable heterogeneity between institutions. ROSE is associated with 3% improvement in adequacy rates but does not explain the variability in results across institutions.

**Category:**

Cytopathology

# First and Only FDA Cleared Digital Cytology System

**Genius™ Cervical AI**

**Genius™ Review Station**

**Genius™ Digital Imager**



## Empower Your Genius With Ours

**Make a Greater Impact on Cervical Cancer**  
with the Advanced Technology of the  
Genius™ Digital Diagnostics System



**Click or Scan**  
to discover more

ADS-04159-001 Rev 001 © 2024 Hologic, Inc. All rights reserved. Hologic, Genius, and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries. This information is intended for medical professionals in the U.S. and other markets and is not intended as a product solicitation or promotion where such activities are prohibited. Because Hologic materials are distributed through websites, podcasts and tradeshows, it is not always possible to control where such materials appear. For specific information on what products are available for sale in a particular country, please contact your Hologic representative or write to [diagnostic.solutions@hologic.com](mailto:diagnostic.solutions@hologic.com).

**genius™**  
DIGITAL DIAGNOSTICS